AdaptHealth (AHCO) Stock Price, News & Analysis

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AdaptHealth in the last year. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AHCO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AHCO, but not buy additional shares or sell existing shares.
View AHCO analyst ratings or view top-rated stocks.

7 analysts have issued 12 month price targets for AdaptHealth's stock. Their AHCO share price targets range from $6.50 to $21.00. On average, they anticipate the company's stock price to reach $12.10 in the next twelve months. This suggests a possible upside of 28.3% from the stock's current price.
View analysts price targets for AHCO or view top-rated stocks among Wall Street analysts.

AdaptHealth's stock was trading at $7.29 at the beginning of 2024. Since then, AHCO shares have increased by 29.4% and is now trading at $9.43.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our AHCO earnings forecast.

AdaptHealth Corp. (NASDAQ:AHCO) issued its quarterly earnings data on Tuesday, February, 27th. The company reported $0.64 earnings per share for the quarter, topping analysts' consensus estimates of $0.20 by $0.44. The firm earned $858.23 million during the quarter, compared to analyst estimates of $825.94 million. AdaptHealth had a negative net margin of 21.21% and a positive trailing twelve-month return on equity of 8.84%.

ETFs with the largest weight of AdaptHealth (NASDAQ:AHCO) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Invesco S&P SmallCap 600 Pure Value ETF (RZV), Harbor Small Cap Explorer ETF (QWST), Invesco S&P SmallCap Health Care ETF (PSCH) and Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD).Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ).

AdaptHealth issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.3 billion-$3.4 billion, compared to the consensus revenue estimate of $3.3 billion.

Based on aggregate information from My MarketBeat watchlists, some companies that other AdaptHealth investors own include Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), Advance Auto Parts (AAP), American International Group (AIG), Biogen (BIIB), BioMarin Pharmaceutical (BMRN), Bristol-Myers Squibb (BMY), Caterpillar (CAT), Cisco Systems (CSCO) and CVS Health (CVS).

AdaptHealth's stock is owned by many different institutional and retail investors. Top institutional shareholders include Reinhart Partners LLC. (3.17%), Inspirion Wealth Advisors LLC (0.09%), Counterpoint Mutual Funds LLC (0.01%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Aero Holdings Ii Ll Skyknight, Alan G Quasha, Albert A Prast, Christopher J Joyce, Daniel Bunting, David Solomon Williams III, Everest Hill Group Inc, Frank Mullen, James E Flynn, Jason A Clemens, Ronald T Mcdaniel, Shaw Rietkerk, Skyknight Aero Holdings, Llc, Skyknight Capital Fund Ii, LP and Stephen P Griggs.
View institutional ownership trends.

Shares of AHCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.